Volume | 1,705,520 |
|
|||||
News | (1) | ||||||
Day High | 0.8428 | Low High |
|||||
Day Low | 0.75 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
HOOKIPA Pharma Inc | HOOK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.819 | 0.75 | 0.8428 | 0.8061 | 0.85 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,091 | 1,705,520 | $ 0.8070724 | $ 1,376,478 | - | 0.41 - 2.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:29:57 | formt | 875 | $ 0.80 | USD |
HOOKIPA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
68.84M | 83.95M | - | 20.13M | -81.58M | -0.97 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
HOOKIPA Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HOOK Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.77 | 0.87 | 0.70 | 0.8298599 | 2,536,501 | 0.0361 | 4.69% |
1 Month | 0.7255 | 0.90 | 0.70 | 0.8131198 | 1,126,414 | 0.0806 | 11.11% |
3 Months | 0.6211 | 0.90 | 0.60 | 0.7642904 | 705,829 | 0.185 | 29.79% |
6 Months | 0.456 | 1.13 | 0.41 | 0.7860022 | 1,593,271 | 0.3501 | 76.78% |
1 Year | 0.88 | 2.05 | 0.41 | 0.9123372 | 1,251,385 | -0.0739 | -8.40% |
3 Years | 12.30 | 20.00 | 0.41 | 1.98 | 1,217,484 | -11.49 | -93.45% |
5 Years | 14.03 | 20.00 | 0.41 | 2.41 | 764,636 | -13.22 | -94.25% |
HOOKIPA Pharma Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |